Abstract
Bleomycin has potent anti-oncogenic properties for several neoplasms, but drug administration is limited by bleomycin-induced lung fibrosis. Inhibition of the renin-angiotensin system has been suggested to decrease bleomycin toxicity, but the efficacy of such strategies remains uncertain and somewhat contradictory. Our hypothesis is that, besides angiotensin II, other substrates of angiotensin-converting enzyme (ACE), such as the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), play a significant role in controlling fibrosis. We studied bleomycin-induced lung injury in normotensive mice, termed N-KO and C-KO, which have point mutations inactivating either the N- or C-terminal catalytic sites of ACE, respectively. N-KO, but not C-KO mice, have a marked resistance to bleomycin lung injury as assessed by lung histology and hydroxyproline content. To determine the importance of the ACE N-terminal peptide substrate AcSDKP in the resistance to bleomycin injury, N-KO mice were treated with S-17092, a prolyl-oligopeptidase inhibitor that inhibits the formation of AcSDKP. In response to bleomycin injection, S-17092-treated N-KO mice developed lung fibrosis similar to wild-type mice. In contrast, the administration of AcSDKP ...Continue Reading
References
Apr 1, 1988·Journal of Clinical Pathology·T AshcroftV Timbrell
Dec 1, 1983·Cancer Treatment Reviews·F M MuggiaB I Sikic
May 11, 1995·Nature·J H KregeO Smithies
Feb 24, 1995·The Journal of Biological Chemistry·A RousseauP Corvol
Feb 1, 1996·The Journal of Clinical Investigation·M AziziJ Ménard
Mar 19, 1999·Hypertension·M AziziJ Ménard
Apr 20, 1999·Biochemical and Biophysical Research Communications·H BarelliF Checler
Mar 21, 2002·Clinical and Experimental Pharmacology & Physiology·M AziziJ Ménard
May 11, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·Luis A OrtizPhilip J Kadowitz
Jun 1, 2002·Journal of the American Society of Nephrology : JASN·Qing WangMichel Burnier
Mar 28, 2003·Journal of the American Society of Nephrology : JASN·Keizo KanasakiMasakazu Haneda
May 20, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Richard P MarshallGeoffrey J Laurent
Dec 10, 2003·Hypertension·Craig LumWilliam H Beierwaltes
Dec 24, 2003·Hypertension·Fang YangOscar A Carretero
Dec 25, 2003·Thorax·M OtsukaS Abe
Feb 6, 2004·The Journal of Biological Chemistry·Sebastien FuchsKenneth E Bernstein
Mar 24, 2004·Hypertension·Maria A CavasinOscar A Carretero
Apr 13, 2004·Journal of Hypertension·Saman RasoulNour-Eddine Rhaleb
Feb 3, 2005·Nature Reviews. Cancer·Jingyang Chen, JoAnne Stubbe
Mar 1, 2005·Diabetes·Kazuyuki ShibuyaDaisuke Koya
Apr 2, 2005·The European Respiratory Journal·K A KeoghA H Limper
Oct 28, 2005·The American Journal of Pathology·William E LawsonTimothy S Blackwell
Nov 5, 2005·Nature Medicine·Sebastien FuchsKenneth E Bernstein
Apr 8, 2006·Thorax·M Molina-MolinaA Xaubet
Oct 10, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Jia L ZhuoNour-Eddine Rhaleb
May 2, 2007·Hypertension·Maria A CavasinOscar A Carretero
Nov 13, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·Bethany B Moore, Cory M Hogaboam
Dec 26, 2007·Hypertension·Sebastien FuchsKenneth E Bernstein
Dec 29, 2007·The Journal of Pathology·T A Wynn
May 27, 2008·Respiratory Research·Yuko WasedaShinji Nakao
Citations
May 21, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Romer A Gonzalez-VillalobosKenneth E Bernstein
Jan 29, 2013·Clinical and Experimental Pharmacology & Physiology·Ross G DouglasEdward D Sturrock
Dec 22, 2012·Pharmacological Reviews·Kenneth E BernsteinRhian M Touyz
Dec 29, 2011·Hypertension·Frank S OngKenneth E Bernstein
Feb 23, 2012·Hypertension·Xiao Z ShenKenneth E Bernstein
Dec 1, 2011·Fibrogenesis & Tissue Repair·Megumi KanasakiKeizo Kanasaki
Nov 22, 2013·PloS One·Wen-Jie JiLu-Qing Wei
Feb 8, 2014·PloS One·Sergei M DanilovJoe G N Garcia
May 2, 2014·BioMed Research International·Takako NagaiDaisuke Koya
Jun 23, 2015·Expert Opinion on Biological Therapy·Enrico ConteCarlo Vancheri
Jul 19, 2011·Pharmacology & Therapeutics·Gustavo B MenezesMauro M Teixeira
Dec 7, 2010·Current Opinion in Pharmacology·Kenneth E BernsteinSebastien Fuchs
Sep 11, 2013·Clinical Science·Ross G DouglasEdward D Sturrock
Mar 1, 2011·The Biochemical Journal·Mohd AkifK Ravi Acharya
Jul 1, 2014·Clinical and Experimental Nephrology·Takako NagaiKeizo Kanasaki
May 2, 2014·Frontiers in Pharmacology·Keizo KanasakiDaisuke Koya
Sep 1, 2016·Scientific Reports·Wang XiaojunYang Fang
Dec 15, 2015·PloS One·Ayanda Trevor MnguniBongani M Mayosi
Jul 19, 2016·Scientific Reports·Swayam Prakash SrivastavaDaisuke Koya
Dec 5, 2017·JCI Insight·Philip J O'ReillyJ Edwin Blalock
Aug 29, 2018·British Journal of Pharmacology·Wei-Qiang TanKenneth E Bernstein
Sep 7, 2018·Journal of the American Society of Nephrology : JASN·Masahiro EriguchiJorge F Giani
Mar 23, 2019·IUBMB Life·Xutao ZhangMeng Li
Mar 12, 2019·Canadian Journal of Physiology and Pharmacology·Kamal M KassemNour-Eddine Rhaleb
Sep 26, 2015·Scientific Reports·Geoffrey MasuyerK Ravi Acharya
Jul 1, 2019·Journal of Leukocyte Biology·Flávia RagoMauro Martins Teixeira
Jan 31, 2020·Journal of Diabetes Investigation·Keizo Kanasaki
Mar 31, 2016·Oncotarget·Enrico ConteCarlo Vancheri
Oct 2, 2020·Cancers·Fabian Bernhard Pallasch, Udo Schumacher
Dec 29, 2020·Expert Opinion on Investigational Drugs·Roberto SpoladoreGabriele Fragasso
Mar 31, 2021·Molecular and Cellular Endocrinology·Jorge F GianiKenneth E Bernstein
Apr 17, 2021·BMC Genomics·Yuanyuan LiLeping Li